Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
anemia | EFO_0004272 | D000740 | D64.9 |
Expiration | Code | ||
---|---|---|---|
luspatercept, Reblozyl, Celgene Corporation, a Bristol-Myers Squibb Company | |||
2030-08-28 | Orphan excl. |
Code | Description |
---|---|
J0896 | Injection, luspatercept-aamt, 0.25 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Myelodysplastic syndromes | D009190 | — | D46 | 3 | 8 | 6 | 1 | 2 | 18 |
Anemia | D000740 | HP_0001903 | D64.9 | 1 | 6 | 1 | 1 | — | 9 |
Beta-thalassemia | D017086 | Orphanet_848 | D56.1 | — | 3 | 2 | 1 | 1 | 7 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Primary myelofibrosis | D055728 | — | D47.4 | — | 1 | 1 | — | — | 2 |
Erythrocyte transfusion | D017707 | — | — | — | — | 1 | — | — | 1 |
Myeloproliferative disorders | D009196 | — | D47.1 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Thalassemia | D013789 | EFO_1001996 | D56 | — | 1 | — | — | — | 1 |
Alpha-thalassemia | D017085 | Orphanet_846 | D56.0 | — | 1 | — | — | — | 1 |
Thrombocytosis | D013922 | HP_0001894 | D75.83 | — | 1 | — | — | — | 1 |
Aplastic anemia | D000741 | HP_0001915 | D61.9 | — | 1 | — | — | — | 1 |
Drug common name | Luspatercept |
INN | luspatercept |
Description | Luspatercept |
Classification | Protein |
Drug class | receptor molecules or membrane ligands, natural, modified or modified: transforming growth factor receptors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | 1373715-00-4 |
RxCUI | 2262544 |
ChEMBL ID | CHEMBL3039545 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB12281 |
UNII ID | AQK7UBA1LS (ChemIDplus, GSRS) |